Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4652W HIGH $2.54
Volume
225.41 K
Value Traded
86.27 K
Short % Float
0.08%
-22.89%Week
-39.24%1 Month
-33.33%3 Month
-62.79%6 Month
-80.47%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.31 M
EPS (TTM)
-1.12
P/E Ratio
-
Ent. Value
-8.11 M
Total Shares
46.49 M
Float Shares
33.07 M
Insiders
28.87%
Institutions
40.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NSPR Catalyst Timeline
Dated clinical, regulatory and corporate events for InspireMD Inc.
Past FDA Catalysts and PDUFA Decisions
How NSPR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
InspireMD Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NSPR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CGuard Prime 80 cm | prevention of stroke | 2026-06-11 | 100% acute device success rate; no deaths; no strokes; no myocardial infarctions; no stent thrombosis; complete stent patency observed at 30 daysRead More | InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR ProceduresRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stuka PaulDirector | Buy | 20,000 667,871 held | $0.88 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NSPR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 % (-100 %) | 2.19 M | 3.13 M |
NSPR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NSPR ranks across every disease it competes in
Competitive Position is a premium feature
See how NSPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNSPR News
NSPRInspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
InspireMD has amended its Series J and K warrants to align with the anticipated FDA approval of the CGuard Prime 80 cm, expected in Q4 2026. The amendments aim to provide up to $11 million in gross proceeds to support the product launch and ongoing initiatives. The company emphasizes the importance of these changes for its commercial strategy and market expansion.
Read more →NSPRInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD has approved inducement grants of 23,764 shares of restricted stock to a new non-executive employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of InspireMD's 2024 Inducement Plan and are aimed at attracting new talent. The shares will vest over several years, contingent on continued employment.
Read more →NSPRInspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
InspireMD, Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14th. The company aims to showcase its CGuard® Prime carotid stent system, which is designed to prevent strokes. A live audio webcast will be accessible on their investor page, enhancing investor engagement.
Read more →NSPR▼ -10.4%on this news
InspireMD Reports Second Quarter 2026 Financial Results
InspireMD, Inc. reported its financial results for Q2 2026, showing a total revenue of $1.8 million, consistent with Q2 2025. The company experienced a 21% revenue growth in international markets, offset by a negative U.S. revenue due to a product recall. Key highlights include successful outcomes from clinical trials and the appointment of a new sales leader to support the U.S. market re-launch. The company anticipates significant cost savings and is in discussions with the FDA regarding regulatory submissions.
Read more →NSPRInspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
InspireMD has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. With over 30 years of experience in medical device sales, Kennedy previously supported the U.S. launch of the CGuard Prime system. Her return is seen as a strategic move to enhance InspireMD's commercial efforts ahead of the anticipated U.S. approval and relaunch of the CGuard platform.
Read more →NSPR▼ -5.9%on this newsshared move
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
InspireMD announced positive 30-day outcomes from the CGUARDIANS II clinical trial for its CGuard Prime 80 cm carotid stent used in TCAR procedures. The trial reported a 100% acute device success rate, with no deaths or major adverse events. The company anticipates potential FDA approval in the latter half of the year, aiming to enhance its presence in the TCAR market.
Read more →NSPR▼ -7.2%on this newsshared move
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
InspireMD has announced the enrollment of the first patient in the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system, intended for use in transcarotid artery revascularization procedures. This study aims to evaluate the safety and efficacy of the SwitchGuard NPS in providing cerebral embolic protection. The initiative is seen as a significant advancement in the company's efforts to improve patient safety and stroke prevention.
Read more →NSPRInspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
InspireMD, Inc. announced its participation in the Bank of America Securities 2026 Global Healthcare Conference scheduled for May 13th. The company will present its CGuard®Prime carotid stent system, aimed at preventing strokes. A live audio webcast will be available for investors, enhancing transparency and engagement.
Read more →NSPRInspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
InspireMD has voluntarily recalled its CGuard® Prime 135 cm carotid stent delivery system after performance issues were identified during a controlled launch. This decision does not affect the safety of previously implanted CGuard stents, which continue to demonstrate strong clinical outcomes. The company anticipates FDA approval for its original delivery system in Q3 2026 and is implementing design improvements for the recalled product.
Read more →NSPRInspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
InspireMD, Inc. has received FDA approval for its Investigational Device Exemption application to begin the CGUARDIANS III pivotal study of the SwitchGuard neuro protection system. This study will utilize enhancements from a previous IDE approval and is aimed at improving outcomes in transcarotid artery revascularization procedures. The company anticipates a commercial launch in 2027, contingent on further approvals.
Read more →NSPRInspireMD Reports First Quarter 2026 Financial Results
InspireMD reported its financial results for the first quarter of 2026, highlighting a revenue of $3.4 million, which marks a 122% increase compared to the same period last year. The company received FDA approval to initiate the CGUARDIANS III clinical trial for its SwitchGuard neuro protection system. Despite the positive revenue growth, InspireMD is facing challenges due to a voluntary pause in the commercialization of its CGuard Prime 135 cm system in the U.S. and anticipates financial implications from a recall of the device. Nevertheless, the company is optimistic about upcoming FDA approvals that could enhance market opportunities.
Read more →NSPRInitiates Voluntary U.S. Recall of CGuard Prime 135 cm Stent Delivery System
InspireMD has announced a voluntary recall of its CGuard Prime 135 cm carotid stent delivery system in consultation with the FDA due to performance issues during its controlled launch. Despite this setback, the company continues to experience significant global demand, reporting a 53% increase in year-over-year sales. InspireMD plans to enhance the delivery system's technical performance and anticipates receiving FDA approval for its original delivery system in Q3 2026. The recall affects U.S. commercialization, leading to the withdrawal of full-year revenue guidance.
Read more →NSPR▼ -5.8%on this newsshared move
InspireMD to Announce First Quarter 2026 Financial Results
InspireMD, Inc. plans to release its first quarter financial results on May 4, 2026. The announcement will be accompanied by a conference call at 4:30 p.m. Eastern Time to discuss the results and recent highlights. Interested participants can register online for the call and access the webcast.
Read more →NSPRInspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
InspireMD, Inc. (Nasdaq: NSPR) will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026. The event will feature a live audio webcast available on the company's investor page. InspireMD aims to set a standard in carotid stenting with its CGuard®Prime system, enhancing stroke prevention.
Read more →NSPRInspireMD Reports Fourth Quarter and Full Year 2025 Financial Results
InspireMD, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a revenue increase of 62% in Q4 compared to the same period the previous year. The company has achieved strong commercial traction in the U.S. with its CGuard Prime stent and completed enrollment in the CGUARDIANS II pivotal trial. Despite the revenue growth, InspireMD reported a higher net loss of $11.8 million for Q4 2025, necessitating increased operating expenses as the company invests in resources to support its market growth. Looking ahead, InspireMD anticipates revenue growth of 45% to 65% for 2026, estimating revenues between $13 million and $15 million.
Read more →About InspireMD Inc.
Headquarters6303 WATERFORD DISTRICT DRIVE, MIAMI, FL, 33126
BIOPHARMAWATCH ELITE PLUS
Trade the next NSPR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime